TW201632551A - 雙特異性抗體及用於眼科學之方法 - Google Patents
雙特異性抗體及用於眼科學之方法 Download PDFInfo
- Publication number
- TW201632551A TW201632551A TW104136909A TW104136909A TW201632551A TW 201632551 A TW201632551 A TW 201632551A TW 104136909 A TW104136909 A TW 104136909A TW 104136909 A TW104136909 A TW 104136909A TW 201632551 A TW201632551 A TW 201632551A
- Authority
- TW
- Taiwan
- Prior art keywords
- hvr
- amino acid
- seq
- acid sequence
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/08—Mydriatics or cycloplegics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14192517 | 2014-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201632551A true TW201632551A (zh) | 2016-09-16 |
Family
ID=51868112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW104136909A TW201632551A (zh) | 2014-11-10 | 2015-11-09 | 雙特異性抗體及用於眼科學之方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10730938B2 (2) |
| EP (1) | EP3218399A1 (2) |
| JP (1) | JP2017537896A (2) |
| KR (1) | KR20170080584A (2) |
| CN (1) | CN107074941A (2) |
| AR (1) | AR102592A1 (2) |
| AU (1) | AU2015345323A1 (2) |
| BR (1) | BR112017009764A2 (2) |
| CA (1) | CA2963175A1 (2) |
| IL (1) | IL251128A0 (2) |
| MX (1) | MX2017005977A (2) |
| RU (1) | RU2017120360A (2) |
| SG (1) | SG11201703428SA (2) |
| TW (1) | TW201632551A (2) |
| WO (1) | WO2016075037A1 (2) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5616428B2 (ja) | 2009-04-07 | 2014-10-29 | ロシュ グリクアート アクチェンゲゼルシャフト | 三価の二重特異性抗体 |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| CA2963606A1 (en) * | 2014-11-10 | 2016-05-19 | F.Hoffmann-La Roche Ag | Anti-ang2 antibodies and methods of use |
| CN107148429B (zh) | 2014-11-10 | 2021-12-03 | 豪夫迈·罗氏有限公司 | 抗-pdgf-b抗体和使用方法 |
| AU2015345323A1 (en) | 2014-11-10 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific antibodies and methods of use in ophthalmology |
| EP3218402A1 (en) | 2014-11-10 | 2017-09-20 | F. Hoffmann-La Roche AG | Anti-il-1beta antibodies and methods of use |
| CN107001482B (zh) | 2014-12-03 | 2021-06-15 | 豪夫迈·罗氏有限公司 | 多特异性抗体 |
| KR102799807B1 (ko) | 2015-12-30 | 2025-04-24 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| KR102543878B1 (ko) | 2016-08-23 | 2023-06-14 | 메디뮨 리미티드 | 항-ｖｅｇｆ-ａ 및 항-ａｎｇ2 항체 및 이의 용도 |
| MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
| CN110818793A (zh) * | 2018-08-14 | 2020-02-21 | 中山康方生物医药有限公司 | 抗IL-1β的抗体、其药物组合物及其用途 |
| CN119708247A (zh) * | 2018-12-21 | 2025-03-28 | 豪夫迈·罗氏有限公司 | 与VEGF和IL-1β结合的抗体及其使用方法 |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2021198034A1 (en) * | 2020-03-30 | 2021-10-07 | F. Hoffmann-La Roche Ag | Antibody that binds to vegf and pdgf-b and methods of use |
| KR20240023095A (ko) * | 2021-06-04 | 2024-02-20 | 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 | Vegf 및 ang2에 결합하는 이중특이적 결합 분자 및 이의 사용 |
| CN116925234B (zh) * | 2022-04-02 | 2024-05-31 | 合肥星眸生物科技有限公司 | 一种编码抗vegf-a和ang-2双特异性抗体的aav载体 |
| CN117467025B (zh) * | 2023-12-28 | 2024-04-16 | 上海鼎新基因科技有限公司 | 一种抗vegf和补体双功能融合蛋白及其应用 |
| WO2025211874A1 (ko) * | 2024-04-04 | 2025-10-09 | 주식회사 크로스포인트테라퓨틱스 | 인간 항체 fc 변이체 포함 이중항체 및 그 용도 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4935343A (en) | 1986-08-08 | 1990-06-19 | Syntex (U.S.A.) Inc. | Monoclonal antibodies for interleukin-1β |
| GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| EP1481010A2 (en) | 2002-02-28 | 2004-12-01 | Eli Lilly And Company | Anti-interleukin-1 beta analogs |
| ES2263984T3 (es) | 2002-06-28 | 2006-12-16 | Domantis Limited | Ligandos doble-especificos con una vida media serica aumentada. |
| EP1590369B1 (en) | 2003-01-24 | 2016-03-16 | Applied Molecular Evolution, Inc. | Human il-1 beta antagonists |
| ATE435870T1 (de) | 2003-01-28 | 2009-07-15 | Academisch Ziekenhuis Leiden | Aus ll-37 abgeleiteten peptidinhibitoren von toxinen |
| WO2005052002A2 (en) | 2003-11-20 | 2005-06-09 | Massachusetts Institute Of Technology | Single-domain antibodies and uses thereof |
| US20050282233A1 (en) * | 2004-03-05 | 2005-12-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for VEGF/PDGF family of growth factors |
| BRPI0519596B1 (pt) | 2004-12-21 | 2022-01-18 | Astrazeneca Ab | Agente de ligação alvejado, anticorpo monoclonal que se liga a angiopoietina-2, molécula de ácido nucleico, vetor, e, uso do agente de ligação alvejado |
| MX2007015476A (es) | 2005-06-14 | 2008-02-25 | Amgen Inc | Formulaciones de proteina autoamortiguadoras. |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP2068925A4 (en) | 2007-05-07 | 2011-08-31 | Medimmune Llc | ANTI-ICOS ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER, TRANSPLANTATIONS AND AUTOIMMUNE DISEASES |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US8293714B2 (en) | 2008-05-05 | 2012-10-23 | Covx Technology Ireland, Ltd. | Anti-angiogenic compounds |
| ES2398693T3 (es) | 2008-06-06 | 2013-03-21 | Xoma Technology Ltd. | Métodos para el tratamiento de la artritis reumatoide |
| RU2368359C1 (ru) | 2008-07-22 | 2009-09-27 | Государственное учреждение "УФИМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ" Академии наук Республики Башкортостан (УфНИИ ГБ АН РБ) | Способ лечения возрастной макулярной дегенерации |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| SG172855A1 (en) | 2009-01-29 | 2011-08-29 | Abbott Lab | Il-1 binding proteins |
| IN2012DN02634A (2) | 2009-10-15 | 2015-09-04 | Abbvie Inc | |
| TWI426920B (zh) * | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
| KR20130065662A (ko) | 2010-05-07 | 2013-06-19 | 조마 테크놀로지 리미티드 | ⅠＬ-1β 관련 병태의 치료 방법 |
| RU2013110844A (ru) | 2010-08-13 | 2014-09-20 | Дженентек, Инк. | АНТИТЕЛА ПРОТИВ IL-1β И IL-18, ИСПОЛЬЗУЕМЫЕ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ |
| JP5866130B2 (ja) | 2010-09-10 | 2016-02-17 | アペクシジェン， インコーポレイテッド | 抗ＩＬ−１β抗体およびその使用方法 |
| CN103517921B (zh) | 2010-12-21 | 2017-07-18 | Abbvie 公司 | IL‑1‑α和‑β双特异性双重可变结构域免疫球蛋白及其用途 |
| EP2686345B1 (en) | 2011-03-16 | 2018-04-25 | Amgen Inc. | Fc variants |
| MX358726B (es) | 2011-06-29 | 2018-09-03 | Amgen Inc | Biomarcador predictivo de supervivencia en el tratamiento de carcinoma de celulas renales. |
| CA2877584A1 (en) * | 2012-06-28 | 2014-01-03 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
| LT3495387T (lt) | 2012-07-13 | 2021-11-25 | Roche Glycart Ag | Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti |
| CN104661679A (zh) | 2012-09-28 | 2015-05-27 | 勃林格殷格翰国际有限公司 | 包含双重血管生成素-2/Dll4结合物和抗VEGF药剂的药物组合 |
| JP2015532272A (ja) | 2012-09-28 | 2015-11-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 二重アンジオポエチン−２／Ｄｌｌ４結合剤および抗ＶＥＧＦ−Ｒ剤を含む薬学的組み合わせ |
| EP2916827B1 (en) | 2012-11-08 | 2020-06-10 | Clearside Biomedical Inc. | Methods for the treatment of ocular disease in human subjects |
| HK1216428A1 (zh) * | 2012-11-09 | 2016-11-11 | 辉瑞公司 | 血小板衍生生长因子b之特异性抗体及其组合物和用途 |
| JO3405B1 (ar) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| CN105324396A (zh) | 2013-03-15 | 2016-02-10 | 艾伯维公司 | 针对IL-1β和/或IL-17的双重特异性结合蛋白 |
| KR20210094669A (ko) * | 2013-04-29 | 2021-07-29 | 에프. 호프만-라 로슈 아게 | 인간 fcrn-결합 변형된 항체 및 사용 방법 |
| KR20160085888A (ko) | 2013-12-20 | 2016-07-18 | 에프. 호프만-라 로슈 아게 | 항-ang2 항체 및 cd40 작용제를 사용한 조합 요법 |
| RU2727639C2 (ru) | 2014-01-15 | 2020-07-22 | Ф.Хоффманн-Ля Рош Аг | Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а |
| UA117289C2 (uk) * | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
| EP3218402A1 (en) | 2014-11-10 | 2017-09-20 | F. Hoffmann-La Roche AG | Anti-il-1beta antibodies and methods of use |
| CA2963606A1 (en) | 2014-11-10 | 2016-05-19 | F.Hoffmann-La Roche Ag | Anti-ang2 antibodies and methods of use |
| CN107148429B (zh) | 2014-11-10 | 2021-12-03 | 豪夫迈·罗氏有限公司 | 抗-pdgf-b抗体和使用方法 |
| AU2015345323A1 (en) | 2014-11-10 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific antibodies and methods of use in ophthalmology |
| WO2016209972A1 (en) | 2015-06-26 | 2016-12-29 | Amgen Inc. | Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor |
| MX2019014199A (es) | 2017-06-02 | 2020-01-23 | Boehringer Ingelheim Int | Tratamiento de combinacion antineoplasico. |
-
2015
- 2015-11-06 AU AU2015345323A patent/AU2015345323A1/en not_active Abandoned
- 2015-11-06 CN CN201580060833.XA patent/CN107074941A/zh active Pending
- 2015-11-06 JP JP2017525022A patent/JP2017537896A/ja active Pending
- 2015-11-06 MX MX2017005977A patent/MX2017005977A/es unknown
- 2015-11-06 KR KR1020177011694A patent/KR20170080584A/ko not_active Withdrawn
- 2015-11-06 CA CA2963175A patent/CA2963175A1/en not_active Abandoned
- 2015-11-06 RU RU2017120360A patent/RU2017120360A/ru not_active Application Discontinuation
- 2015-11-06 WO PCT/EP2015/075879 patent/WO2016075037A1/en not_active Ceased
- 2015-11-06 BR BR112017009764A patent/BR112017009764A2/pt not_active Application Discontinuation
- 2015-11-06 SG SG11201703428SA patent/SG11201703428SA/en unknown
- 2015-11-06 EP EP15790946.6A patent/EP3218399A1/en not_active Withdrawn
- 2015-11-09 AR ARP150103645A patent/AR102592A1/es unknown
- 2015-11-09 TW TW104136909A patent/TW201632551A/zh unknown
-
2017
- 2017-03-13 IL IL251128A patent/IL251128A0/en unknown
- 2017-05-09 US US15/590,176 patent/US10730938B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017009764A2 (pt) | 2018-02-20 |
| IL251128A0 (en) | 2017-04-30 |
| RU2017120360A3 (2) | 2019-10-18 |
| CN107074941A (zh) | 2017-08-18 |
| CA2963175A1 (en) | 2016-05-19 |
| KR20170080584A (ko) | 2017-07-10 |
| US20170240629A1 (en) | 2017-08-24 |
| US10730938B2 (en) | 2020-08-04 |
| JP2017537896A (ja) | 2017-12-21 |
| AR102592A1 (es) | 2017-03-08 |
| RU2017120360A (ru) | 2018-12-13 |
| EP3218399A1 (en) | 2017-09-20 |
| SG11201703428SA (en) | 2017-05-30 |
| WO2016075037A1 (en) | 2016-05-19 |
| MX2017005977A (es) | 2017-06-29 |
| AU2015345323A1 (en) | 2017-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10730938B2 (en) | Bispecific antibodies and methods of use in ophthalmology | |
| US20230183349A1 (en) | Anti-pd1 antibodies and methods of use | |
| US10344085B2 (en) | Anti-IL-1beta antibodies | |
| US10087246B2 (en) | Anti-PDGF-B antibodies and methods of use | |
| TW201630935A (zh) | 抗ａｎｇ２抗體及使用方法 | |
| JP7436365B2 (ja) | 抗ｖｅｇｆ抗体及び使用の方法 | |
| EP4688855A1 (en) | Anti-alpha v beta 8 integrin antibodies and methods of use | |
| HK1236207A1 (en) | Bispecific antibodies and methods of use in ophthalmology | |
| HK1238257A1 (en) | Anti-il-1beta antibodies and methods of use | |
| HK1239711A1 (en) | Anti-pdgf-b antibodies and methods of use | |
| HK1259019B (zh) | 抗pd1抗体及使用方法 | |
| HK1239711B (zh) | 抗-pdgf-b抗体和使用方法 |